Lifespan Vision Ventures led Remedium Bio, Inc.’s $10 million Series A financing and completed the round’s initial closing, with participation from Eli Lilly and Company and HKX Capital; Harry Robb of Lifespan Vision Ventures has joined Remedium’s board.
The financing will support advancement of Remedium’s lead programs, continued platform expansion and preparation for first-in-human clinical studies.
The company claims it is developing durable protein therapeutics designed to enable controlled, long-lasting expression of therapeutic proteins following minimally invasive subcutaneous administration by harnessing adipocytes as a durable site for therapeutic protein production, with the potential to provide multi-year benefit and adjustable dosing for patients with chronic diseases.
Remedium’s proprietary Prometheus platform aims to replace many subcutaneously administered protein therapies with single-injection, adjustable gene therapies, and the company’s pipeline includes programs targeting endocrinology, immunology, neurology, musculoskeletal and cardiometabolic diseases.
The financing follows recent progress across the company’s preclinical programs and strategic collaborations and is expected to support key platform milestones.
